The new indication application is primarily based on the results of the pivotal Phase II clinical study MIZAR-003. MIZAR-003 ...
The Company will initiate its planned clinical study of BIO 300 Injectable Suspension, subject to Institutional Review Board ...
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial ...
AM ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value ...
Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri”) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO”) today announced a definitive ...
An accomplished biotechnology executive, Ms. Pussinen brings more than 30 years of global leadership experience spanning ...
Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: ...
After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...
IAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical ...
While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing small molecule therapeutics ...
October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results